PCH
BIO icon

Polar Capital Holdings’s Bio-Rad Laboratories Class A BIO Stock Holding History

Polar Capital Holdings’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-67,188
Closed -$23.2M – 277
2024
Q1 		$23.2M Buy
67,188
+14,462
+27% +$4.76M 0.12% 138
2023
Q4 		$17M Buy
52,726
+11,151
+27% +$3.5M 0.1% 149
2023
Q3 		$14.9M Buy
41,575
+16,824
+68% +$6.49M 0.11% 158
2023
Q2 		$9.38M Sell
24,751
-123,156
-83% -$50.1M 0.05% 202
2023
Q1 		$70.9M Buy
147,907
+37,863
+34% +$17.7M 0.46% 63
2022
Q4 		$46.3M Buy
110,044
+6,390
+6% +$2.58M 0.37% 87
2022
Q3 		$43.2M Sell
103,654
-11,405
-10% -$5.69M 0.28% 85
2022
Q2 		$57M Buy
115,059
+3,263
+3% +$1.7M 0.33% 73
2022
Q1 		$63M Buy
111,796
+7,900
+8% +$4.76M 0.28% 84
2021
Q4 		$78.5M Buy
103,896
+1,950
+2% +$1.46M 0.29% 78
2021
Q3 		$76M Sell
101,946
-95,713
-48% -$71.7M 0.31% 76
2021
Q2 		$127M Buy
197,659
+9,765
+5% +$5.94M 0.55% 36
2021
Q1 		$107M Buy
187,894
+24,900
+15% +$14.7M 0.66% 41
2020
Q4 		$95M Buy
+162,994
New +$92.8M 0.58% 43

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Polar Capital Holdings's BIO Position: Q2 2024 in Review

Polar Capital Holdings sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 67,188 shares — an estimated $23.2M sold.

Polar Capital Holdings first reported a position in BIO in Q4 2020 and held it in 14 quarters. The position peaked at $127M in Q2 2021. 440 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

  • Polar Capital Holdings reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
  • Polar Capital Holdings sold 67,188 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $23.2M.
  • Polar Capital Holdings first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 14 quarters.
  • Polar Capital Holdings's Bio-Rad Laboratories Class A position peaked at $127M in Q2 2021.
  • 440 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Polar Capital Holdings's 13F filing for Q2 2024, filed 14 Aug 2024.